Venus Medtech (Hangzhou) (HKSE:02500) Equity-to-Asset : 0.66 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Venus Medtech (Hangzhou)'s Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,194.5 Mil. Venus Medtech (Hangzhou)'s Total Assets for the quarter that ended in Dec. 2023 was HK$4,827.6 Mil. Therefore, Venus Medtech (Hangzhou)'s Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.66.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s Equity-to-Asset or its related term are showing as below:

HKSE:02500' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.68 Max: 0.89
Current: 0.66

During the past 7 years, the highest Equity to Asset Ratio of Venus Medtech (Hangzhou) was 0.89. The lowest was 0.37. And the median was 0.68.

HKSE:02500's Equity-to-Asset is ranked better than
53.1% of 872 companies
in the Medical Devices & Instruments industry
Industry Median: 0.64 vs HKSE:02500: 0.66

Venus Medtech (Hangzhou) Equity-to-Asset Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Equity-to-Asset Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.83

0.88

0.89

0.68

0.66

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial							0.89	0.70	0.68	0.66	0.66

Competitive Comparison of Venus Medtech (Hangzhou)'s Equity-to-Asset

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou)'s Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Equity-to-Asset falls into.

Venus Medtech (Hangzhou) Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Venus Medtech (Hangzhou)'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3194.543	/	4827.627
	=	0.66

Venus Medtech (Hangzhou)'s Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3194.543	/	4827.627
	=	0.66

Venus Medtech (Hangzhou) (HKSE:02500) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Venus Medtech (Hangzhou) Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines